Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eicosapentaenoic acid + fluoxetine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy consisting of eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant. EPA is thought to exert neuroprotective and anti-inflammatory effects in the brain, while fluoxetine increases synaptic serotonin levels by inhibiting its reuptake. Clinical studies have shown that both agents individually are effective in reducing depressive symptoms in major depressive disorder (MDD). However, their combination has demonstrated superior efficacy compared to either agent alone for the treatment of MDD. The mechanism likely involves complementary modulation of neurotransmitter systems and inflammatory pathways relevant to depression[1][2][4].
- Other names
- EPA + fluoxetineomega-3 fatty acid eicosapentaenoic acid + fluoxetine
02
Targets
SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)Prostamide R (Prostamide receptor)CysLTR (Cysteinyl leukotriene receptor family)mAChR (Muscarinic acetylcholine receptors)HTR2C (5-hydroxytryptamine 2C receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on eicosapentaenoic acid + fluoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eicosapentaenoic acid + fluoxetine.